파브리병 시장 보고서(2026년)

Fabry disease is a rare genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A, resulting in the accumulation of fat within the body's cells and organs. Treatment aims to manage symptoms, reduce organ damage, and improve the quality of life for affected individuals.

The main types of Fabry disease include type 1, type 2, and other forms. Type 1 Fabry disease typically begins in childhood and is caused by a near-complete deficiency of alpha-galactosidase A, leading to fat buildup in cells and organs. Treatments include enzyme replacement therapy, oral therapy, adjunct therapies, and other approaches. Diagnosis is performed through blood tests, genetic tests, parenteral tests, and other diagnostic methods. These treatments are distributed via hospital pharmacies, retail pharmacies, and online pharmacies, and are used by hospitals, homecare providers, specialty clinics, and other healthcare facilities.

Tariffs have affected the fabry disease market by increasing the cost of imported biologics, enzyme replacement therapies, and diagnostic reagents used in disease management. These impacts have been most pronounced in hospital and specialty clinic segments in North America and Europe. Asia-Pacific markets have faced supply constraints due to dependence on imported rare disease drugs. However, tariffs have encouraged localized manufacturing and regional distribution partnerships, supporting improved treatment accessibility.

The fabry disease market research report is one of a series of new reports from The Business Research Company that provides fabry disease market statistics, including fabry disease industry global market size, regional shares, competitors with a fabry disease market share, detailed fabry disease market segments, market trends and opportunities, and any further data you may need to thrive in the fabry disease industry. This fabry disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fabry disease market size has grown strongly in recent years. It will grow from $2.26 billion in 2025 to $2.43 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increased awareness of rare genetic disorders, approval of enzyme replacement therapies, expansion of specialty clinics, growth in genetic screening programs, rising diagnosis rates.

The fabry disease market size is expected to see strong growth in the next few years. It will grow to $3.27 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to advancement in gene-based therapies, expansion of newborn screening programs, increasing healthcare spending on rare diseases, growth in personalized medicine, development of next-generation oral therapies. Major trends in the forecast period include increasing adoption of enzyme replacement therapy, rising focus on rare disease diagnosis, growing use of genetic testing for early detection, expansion of oral and adjunct therapies, increasing patient-centric treatment approaches.

A growing focus on personalized medicine is expected to propel the growth of the Fabry disease market going forward. Personalized medicine is an approach that uses information about a person's genes, environment, and lifestyle to tailor medical care and therapies for better outcomes. The rising emphasis on personalized medicine is driven by its ability to improve treatment effectiveness and reduce side effects by customizing therapies to individual patient needs. In Fabry disease, personalized medicine enables treatment plans to be tailored based on a patient's specific genetic mutation and disease severity, enhancing outcomes while minimizing unnecessary side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, a significant increase from six approvals in 2022. Therefore, the growing focus on personalized medicine is driving the growth of the Fabry disease market.

Major companies operating in the Fabry disease market are focusing on developing innovative therapies, such as PEGylated enzyme replacement therapy (ERT), to enhance treatment efficacy, improve patient compliance, and reduce immunogenic responses associated with conventional ERTs. PEGylated ERT is a modified form of traditional enzyme replacement therapy in which polyethylene glycol (PEG) chains are attached to the enzyme to increase its stability, prolong circulation time in the body, and minimize immune system reactions. For instance, in May 2023, Chiesi Global Rare Diseases, a division of the Chiesi Group, an Italy-based pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for PRX-102 (pegunigalsidase alfa) for the treatment of adult Fabry disease patients. The approval is supported by a robust clinical program involving over 140 patients and long-term follow-up of up to 7.5 years, demonstrating the therapy's efficacy in reducing renal Gb3 deposits, maintaining kidney function, and exhibiting a favorable safety profile.

In March 2024, Centogene N.V., a US-based rare disease diagnostics company, extended its strategic partnership with Takeda Pharmaceutical Company Limited to continue providing access to genetic testing for patients with lysosomal storage disorders (LSDs). Through this partnership extension, Centogene aims to enhance patient access to rapid and reliable diagnostic testing for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome, leveraging its multiomic testing portfolio and diagnostic network to accelerate diagnoses and improve health outcomes for underserved rare disease patient communities. Takeda Pharmaceutical Company Limited is a Japan-based biopharmaceutical company specializing in rare disease therapeutics and enzyme replacement therapies, including those for Fabry disease.

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

North America was the largest region in the fabry disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fabry disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fabry disease market consists of revenues earned by entities by providing services such as genetic counseling, patient support programs, clinical trials and research services, and disease monitoring and management services. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fabry Disease Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses fabry disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fabry disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fabry disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Type 1; Type 2; Other Types
• 2) By Treatment: Enzyme Replacement Therapy; Oral Therapy; Adjunct Therapy; Other Treatments
• 3) By Diagnosis: Blood Test; Genetic Test; Other Diagnosis
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Type 1: Classic Fabry Disease; Later-Onset Fabry Disease
• 2) By Type 2: Cardiovascular-Focused Fabry Disease; Renal-Focused Fabry Disease
• 3) By Other Types: Variant Fabry Disease; X-linked Fabry Disease
• Companies Mentioned: Sanofi S.A.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; JCR Pharmaceuticals Co. Ltd.; Sumitomo Pharma Co. Ltd; Chiesi Farmaceutici S.p.A.; Amicus Therapeutics Inc.; Idorsia Pharmaceuticals Ltd; Sangamo Therapeutics Inc.; uniQure N.V.; Protalix BioTherapeutics Inc.; Spur Therapeutics Inc.; Exegenesis Bio Inc.; ISU ABXIS Co. Ltd.; Eleva GmbH; AceLink Therapeutics Inc.; 4D Molecular Therapeutics Inc.; iBio Inc.; Freeline Therapeutics Holdings plc; Greenovation Biotech GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Fabry Disease Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Fabry Disease Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Fabry Disease Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Fabry Disease Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Enzyme Replacement Therapy
  • 4.2.2 Rising Focus On Rare Disease Diagnosis
  • 4.2.3 Growing Use Of Genetic Testing For Early Detection
  • 4.2.4 Expansion Of Oral And Adjunct Therapies
  • 4.2.5 Increasing Patient-Centric Treatment Approaches

5. Fabry Disease Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare Settings
• 5.4 Diagnostic Laboratories
• 5.5 Research Institutes

6. Fabry Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Fabry Disease Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Fabry Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Fabry Disease Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Fabry Disease Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Fabry Disease Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Fabry Disease Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Fabry Disease Market Segmentation

• 9.1. Global Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Type 1, Type 2, Other Types
• 9.2. Global Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments
• 9.3. Global Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Blood Test, Genetic Test, Other Diagnosis
• 9.4. Global Fabry Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
• 9.5. Global Fabry Disease Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End Users
• 9.6. Global Fabry Disease Market, Sub-Segmentation Of Type 1, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Classic Fabry Disease, Later-Onset Fabry Disease
• 9.7. Global Fabry Disease Market, Sub-Segmentation Of Type 2, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease
• 9.8. Global Fabry Disease Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Variant Fabry Disease, X-linked Fabry Disease

10. Fabry Disease Market Regional And Country Analysis

• 10.1. Global Fabry Disease Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Fabry Disease Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Fabry Disease Market

• 11.1. Asia-Pacific Fabry Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Fabry Disease Market

• 12.1. China Fabry Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Fabry Disease Market

• 13.1. India Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Fabry Disease Market

• 14.1. Japan Fabry Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Fabry Disease Market

• 15.1. Australia Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Fabry Disease Market

• 16.1. Indonesia Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Fabry Disease Market

• 17.1. South Korea Fabry Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Fabry Disease Market

• 18.1. Taiwan Fabry Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Fabry Disease Market

• 19.1. South East Asia Fabry Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Fabry Disease Market

• 20.1. Western Europe Fabry Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Fabry Disease Market

• 21.1. UK Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Fabry Disease Market

• 22.1. Germany Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Fabry Disease Market

• 23.1. France Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Fabry Disease Market

• 24.1. Italy Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Fabry Disease Market

• 25.1. Spain Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Fabry Disease Market

• 26.1. Eastern Europe Fabry Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Fabry Disease Market

• 27.1. Russia Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Fabry Disease Market

• 28.1. North America Fabry Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Fabry Disease Market

• 29.1. USA Fabry Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Fabry Disease Market

• 30.1. Canada Fabry Disease Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Fabry Disease Market

• 31.1. South America Fabry Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Fabry Disease Market

• 32.1. Brazil Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Fabry Disease Market

• 33.1. Middle East Fabry Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Fabry Disease Market

• 34.1. Africa Fabry Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Fabry Disease Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Diagnosis, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Fabry Disease Market Regulatory and Investment Landscape

36. Fabry Disease Market Competitive Landscape And Company Profiles

• 36.1. Fabry Disease Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Fabry Disease Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Fabry Disease Market Company Profiles
  • 36.3.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. JCR Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Sumitomo Pharma Co. Ltd Overview, Products and Services, Strategy and Financial Analysis

37. Fabry Disease Market Other Major And Innovative Companies

• Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

38. Global Fabry Disease Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Fabry Disease Market

40. Fabry Disease Market High Potential Countries, Segments and Strategies

• 40.1 Fabry Disease Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Fabry Disease Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Fabry Disease Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer